Hypnosis for Sleep Quality in Caregivers of Individuals With Alzheimer's Disease

Poor Quality Sleep Clinical Trial

Official title:

Feasibility of Self-Administered Hypnosis for Sleep Quality in Caregivers of Individuals With Alzheimer's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04779866
• Other study ID #: NCT09384
• Secondary ID: 3R01AT009384-04S
• Status: Completed
• Phase: N/A
• Start date: March 30, 2021
• Est. completion date: June 1, 2023

Study information

• Verified date: July 2023
• Source: Baylor University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The long-range goal is to identify an efficacious and practical intervention to improve sleep quality and duration for family caregivers of individuals with Alzheimer's disease and related dementias (ADRD). The main goal of this study is to determine feasibility of a self-administered hypnosis intervention with caregivers of individuals with ADRD by randomizing eligible participants into one of two study arms, self-administered hypnosis (treatment group) or sham white noise hypnosis (control group). The investigators are also examining the feasibility of accrual, outcome measures (diaries, actigraphy) and study design.

Description:

Study Objectives

Aim 1: Determine the accrual, retention, adherence and feasibility, and randomization to the self-administered hypnosis program among caregivers of individuals with ADRD. Feasibility will be determined by (1) drop-out rate, (2) participants' rating of the program, and (3) participants' rating of treatment satisfaction. Adherence will be determined through at-home practice logs. Essential experience on accrual and retention data as well.

Aim 2: Determine feasibility of measures: PSQI, actigraphy recordings, and sleep diaries to assess sleep quality and duration, as well as feasibility of secondary self-report outcome measures of insomnia severity, stress, cognition, and pain among caregivers.

Aim 3: Determine perceptions of hypnosis and potential barriers for the caregiver population and feedback.

Participant Selection and Recruitment Plan

A sample of 20 caregivers, both male and female, of individuals with ADRD, who suffer from poor sleep will be enrolled in the study. A screening checklist will be used for screening participants who are interested.

Potential participants will be identified (1) via advertisements and press releases, (2) via physician referral, and (3) targeted mailings. Participants eligibility will be determined by criteria listed on a screening checklist. The investigators have used these strategies in prior studies and have demonstrated ability to accrue the required number of participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 1, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Active caregiver to an individual with Alzheimer's disease or its related dementias

2. Self-reported sleep duration of 6 or less hours per day/night as indicated on the PSQI

3. Signed informed consent

4. Access to a computer or mobile device with reliable Internet connection that will allow for the completion of study visits and study materials online

Exclusion Criteria:

1. Use of any prescription or over-the-counter therapy for sleep

2. Severe or unstable medical or psychiatric illness

3. Current use of hypnosis for any condition

4. Inability to speak or understand English

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease (Incl Subtypes)
• Caregiver Stress
• Poor Quality Sleep

Intervention

Behavioral:
• Self-Administered Hypnosis
Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
• Self-Administered White Noise Hypnosis
Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.

Locations

Country	Name	City	State
United States	Baylor University	Waco	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Baylor University	National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Post-Participation Interview	In order to gather qualitative data to improve future studies, participants will be asked to participate in a post-participation interview. An experienced and trained doctoral student will conduct interviews and create summary statements regarding topics including ease of use of the intervention, barriers of using the audio recordings, finding the time to practice, and improvement of the intervention. Interviews will be recorded and transcripts will be typed out.	1 week
Primary	Self-Hypnosis Practice Log	Participants will be instructed in daily practice of hypnosis and asked to keep a daily self-hypnosis practice form during the intervention period.	Through study completion, an average of 7 weeks
Primary	Program Rating Scale	In order to assess participants' perceptions of the value of the hypnosis program they receive, they will be asked "How do participants rate this hypnosis program overall in regard to ease of use?" and "How do participants rate this hypnosis program overall in regard to improving sleep?" Responses will be given on a 10-point scale ranging from 1 (Poor) to 10 (Excellent) at follow-up.	One week
Primary	Treatment Satisfaction Scale	Participants will be asked to rate their overall level of satisfaction with the intervention. A 10-point VAS scale anchored with 0 "Completely Dissatisfied" to 10 "Completely Satisfied" will be given at follow-up.	One week
Primary	Wrist Actigraphy	Wrist actigraphy is a widely used and well-validated measure of sleep duration. Participants will be asked to wear an actigraph (Actiwatch Spectrum Pro), resembling a wrist watch, on their non-dominant wrist. A motion detection device located within the actigraph records movement. After data is collected and stored within the actigraph it can be analyzed with the Actiware software program. This program uses a series of logarithms to measure various factors associated with sleep quality, such as total sleep duration, sleep efficiency, sleep onset latency, and the number of times participants woke during the night. For the present study, participants will be asked to wear the actigraph for one week at baseline and for one week at follow-up.	up to 2 weeks
Primary	Pittsburgh Sleep Quality Index	Participants will be asked to complete the Pittsburgh Sleep Quality Index (PSQI) during screening and at follow-up to measure sleep quality. The PSQI is a 19-item self-report inventory designed to measure sleep quality. The 19 items are grouped into 7 subscales: 1) sleep quality, 2) sleep efficiency, 3) daytime dysfunction, 4) sleep latency, 5) sleep disturbances, 6) sleep duration, and 7) use of sleep medication. These seven subscales are scored on a scale of 0-3 with higher scores indicating greater sleep pathology. Cronbach's alphas for the PSQI range from .70 to .8024.	up to 2 weeks
Primary	Daily Sleep Diaries	A daily sleep diary where participants record time awake and time to bed will be used. Participants will be asked to complete a daily sleep diary upon awakening each morning for a week at baseline, daily during the intervention weeks, and a week at follow-up.	Through study completion, an average of 7 weeks
Primary	Epworth Sleepiness Scale	Participants will be asked to complete the Epworth Sleepiness Scale (ESS) to assess daytime sleepiness. The ESS is an 8-item self-report measure that asks participants to indicate how likely they are to fall asleep while engaging in eight different everyday activities (e.g., watching television, sitting in traffic). Items are scored on a scale from 0-3 with higher scores indicating a greater probability of falling asleep. Previous research indicates that the ESS has a Cronbach's alpha of .8827.	Through study completion, an average of 7 weeks
Primary	Sleep Environment Questionnaire	Participants will be asked to complete the Sleep Environment Questionnaire during baseline and at follow-up. The Sleep Environment Questionnaire is an 11-item self-report measure that asks about the environment in which a person sleeps. Response options include "True," "False," or "Not Applicable."	Through study completion, an average of 7 weeks
Primary	Attitudes Toward Hypnosis Scale	The 14-item Attitudes Toward Hypnosis Scale will be used to assess attitudes toward hypnosis at baseline and at follow-up. This scale has shown internal consistency in previous studies, Cronbach's alpha = .8128. A total attitude toward hypnosis score will be calculated for each participant by summing scores across the 14 items with higher scores indicating more positive attitudes toward hypnosis.	Through study completion, an average of 7 weeks
Secondary	Insomnia Severity Index	Participants will be asked to complete the Insomnia Severity Index (ISS) to measure insomnia symptom severity. The ISS consists of seven items that measure the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as the participant's satisfaction with her current sleep pattern, the extent to which lack of sleep interferes with daily functioning, how noticeable this impairment is to other people, and the extent to which the participant is worried or distressed about their lack of sleep. Items are scored on a scale from 0-4 with total score of 15 or higher indicating the presence of clinical insomnia25. Past research indicates that internal reliability estimates for the ISI range from .74 to .7825.	Through study completion, an average of 7 weeks
Secondary	Perceived Stress Scale	The Perceived Stress Scale (PSS) will be used to measure stress at baseline and follow-up. The PSS includes 14 items that assess levels of perceived stress and to what degree individuals perceive events in their life as stressful during the previous month. Higher scores indicate greater stress. Past research indicates that Cronbach's alpha for the PSS is .8526.	Through study completion, an average of 7 weeks
Secondary	PROMIS Cognitive Function - Short Form	Cognition will be assessed using the PROMIS Cognitive Function - Short Form Scale. This scale includes 8 items and measures self-reported cognitive functioning during the past 7 days. Items are scored from a scale of 1 (Very Often) to 5 (Never). Items are summed to create a total score and higher scores indicate better cognitive functioning.	Through study completion, an average of 7 weeks
Secondary	Pain Visual Analog Scale	Participants will be asked to rate their pain on a 100-mm visual analog scale (VAS) during baseline and follow-up. Participants will be asked to place an "x" along the 100-mm line to indicate the severity of their pain over the past week, with the lower end of the scale being anchored by the phrase "no pain" and the upper end of the scale being anchored by the phrase "the most intense pain possible."	Through study completion, an average of 7 weeks
Secondary	Motivation Scale	Motivation to use hypnosis is an important factor to be assessed. Motivation to use hypnosis to improve sleep quality will be assessed at baseline using a numerical rating scale that states, "How motivated are participants to use hypnosis to improve sleep?" This item will be rated on a scale of 1 (Not Motivated at All) to 10 (Very Motivated).	One week during baseline week